Ruth Perets

4.1k total citations · 3 hit papers
61 papers, 2.7k citations indexed

About

Ruth Perets is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ruth Perets has authored 61 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Ruth Perets's work include Cancer Immunotherapy and Biomarkers (25 papers), Ovarian cancer diagnosis and treatment (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ruth Perets is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Ovarian cancer diagnosis and treatment (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ruth Perets collaborates with scholars based in Israel, United States and Japan. Ruth Perets's co-authors include Ronny Drapkin, Michelle S. Hirsch, Antoîne Italiano, Sarina A. Piha‐Paul, Ronnie Shapira‐Frommer, Jean‐Pierre Delord, Hyun Cheol Chung, Scott K. Pruitt, Alexandra Léary and Lei Xu and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Ruth Perets

57 papers receiving 2.7k citations

Hit Papers

Efficacy and Safety of Pembrolizumab in Previo... 2013 2026 2017 2021 2019 2013 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
    2019 714 citations Hyun Cheol Chung, Willeke Ros et al. Journal of Clinical Oncology profile →
  2. Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models
    2013 402 citations Ruth Perets, Gregory A. Wyant et al. Cancer Cell profile →
  3. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
    2019 325 citations Ruth Perets et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruth Perets Israel 18 1.3k 914 613 546 493 61 2.7k
Kosei Hasegawa Japan 26 1.4k 1.1× 678 0.7× 940 1.5× 508 0.9× 353 0.7× 179 3.0k
Claire Bonneau France 21 1.9k 1.5× 1.2k 1.3× 428 0.7× 450 0.8× 904 1.8× 72 3.5k
John W. Moroney United States 19 874 0.7× 656 0.7× 310 0.5× 438 0.8× 493 1.0× 49 2.5k
Katja Gwin United States 18 659 0.5× 1.3k 1.4× 511 0.8× 285 0.5× 1.3k 2.5× 48 2.6k
Leah Prentice Canada 18 552 0.4× 909 1.0× 1.0k 1.7× 287 0.5× 456 0.9× 26 2.2k
Patricia A. Shaw Canada 29 1.1k 0.8× 976 1.1× 1.4k 2.3× 259 0.5× 623 1.3× 57 3.0k
Sharad Ghamande United States 22 770 0.6× 579 0.6× 476 0.8× 230 0.4× 216 0.4× 114 1.7k
Sharon X. Liang United States 24 1.1k 0.8× 914 1.0× 2.0k 3.3× 547 1.0× 533 1.1× 57 3.2k
Marta Gil-Martín Spain 20 1.2k 0.9× 629 0.7× 232 0.4× 526 1.0× 322 0.7× 108 2.0k

Countries citing papers authored by Ruth Perets

Since Specialization
Citations

This map shows the geographic impact of Ruth Perets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Perets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Perets more than expected).

Fields of papers citing papers by Ruth Perets

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Perets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Perets. The network helps show where Ruth Perets may publish in the future.

Co-authorship network of co-authors of Ruth Perets

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Perets. A scholar is included among the top collaborators of Ruth Perets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Perets. Ruth Perets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrington, Kevin J., Stéphane Champiat, Joshua Brody, et al.. (2025). Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(16). 3400–3411. 10 indexed citations
2.
Schwarz, Norbert Georg, Zvi Vaknin, Ora Rosengarten, et al.. (2025). Increasing incidence of endometrial cancer demands global action. 1(3). e158–e159.
3.
Perets, Ruth, Manish Sharma, John H. Strickler, et al.. (2024). Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications.. Journal of Clinical Oncology. 42(16_suppl). TPS3162–TPS3162.
4.
Sharma, Manish, John H. Strickler, David Sommerhalder, et al.. (2024). First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 3515–3515. 9 indexed citations
5.
Babu, Sunil, Shunsuke Kondo, Alexander I. Spira, et al.. (2023). 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors. Annals of Oncology. 34. S647–S648. 2 indexed citations
6.
7.
Rotow, Julia, Kiyotaka Yoh, Ruth Perets, et al.. (2022). 1185TiP First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors. Annals of Oncology. 33. S1090–S1090. 2 indexed citations
8.
9.
Falchook, Gerald S., Marc Peeters, Sylvie Rottey, et al.. (2021). A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Investigational New Drugs. 39(5). 1284–1297. 47 indexed citations
10.
Katzav, Aviva, Debora Kidron, E. L. Edelstein, et al.. (2020). DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer Letters. 501. 224–233. 13 indexed citations
11.
Gabizón, Alberto, Esther Tahover, Talia Golan, et al.. (2020). Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Investigational New Drugs. 38(5). 1411–1420. 15 indexed citations
12.
Chung, Hyun Cheol, Willeke Ros, Jean‐Pierre Delord, et al.. (2019). Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology. 37(17). 1470–1478. 714 indexed citations breakdown →
13.
Bublik, Débora Rosa, Sarit Aviel‐Ronen, Keren Levanon, et al.. (2018). PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma. Oncogene. 37(17). 2213–2224. 35 indexed citations
14.
Geva, Ravit, Juanita Lopez, Sarah Danson, et al.. (2018). Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging. 46(5). 1092–1101. 15 indexed citations
15.
Gabizon, Alberto, Tal Grenader, Esther Tahover, et al.. (2016). A phase 1B study of pegylated liposomal mitomycin-C prodrug with or without capecitabine and bevacizumab in third line chemotherapy of colorectal cancer. Annals of Oncology. 27. vi202–vi202. 2 indexed citations
16.
Perets, Ruth & Ronny Drapkin. (2015). It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research. Cancer Research. 76(1). 10–17. 90 indexed citations
17.
Perets, Ruth, Gregory A. Wyant, Katherine W. Muto, et al.. (2013). Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. Cancer Cell. 24(6). 751–765. 402 indexed citations breakdown →
18.
Laury, Anna, Ruth Perets, Huiying Piao, et al.. (2011). A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors. The American Journal of Surgical Pathology. 35(6). 816–826. 309 indexed citations
19.
Laury, Anna, Jason L. Hornick, Ruth Perets, et al.. (2010). PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma. The American Journal of Surgical Pathology. 34(5). 627–635. 152 indexed citations
20.
Beigel, Roy, Ruth Perets, & Meir Mouallem. (2009). Acute Kidney Injury, Hepatitis, and CPK Elevation Associated With Nitrofurantoin Therapy. The American Journal of the Medical Sciences. 337(2). 132–133. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kosei Hasegawa Breakdown of academic impact, for papers by Claire Bonneau Breakdown of academic impact, for papers by John W. Moroney Breakdown of academic impact, for papers by Katja Gwin Breakdown of academic impact, for papers by Leah Prentice Breakdown of academic impact, for papers by Patricia A. Shaw Breakdown of academic impact, for papers by Sharad Ghamande Breakdown of academic impact, for papers by Sharon X. Liang Breakdown of academic impact, for papers by Marta Gil-Martín
Rankless by CCL
2026